News and Media
BREAKING NEWS: MMS partners with MIT Julia Lab and University of Maryland to create the Health Analytics Collective
by MIT news, January 25, 2019
The timeline to market a new drug or medical device, from the point of discovery to U.S. Food and Drug Administration approval, can stretch to a decade. By pooling its industry experience and technology, a new health research supergroup led by the Julia Lab within the MIT Computer Science and Artificial Intelligence Laboratory aims to significantly shorten the approval process for pharmaceutical and health care groups.
CANTON, Mich. (December 19, 2018) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that the company will host the Michigan SAS Users Group (MSUG) for their first quarter meeting on Wednesday, March 13, 2019.
Vivozon’s Non-Opioid Pain Killer has been granted the FDA’s Fast Track Designation through Regulatory Strategy Support from MMS
CANTON, Mich. (November 8, 2018) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that the company has successfully assisted Korea-based Vivozon Inc. in achieving a Fast Track Designation from the Food and Drug Administration (FDA) for VVZ-149, a non-opioid pain killer.
Chris Hurley Asked to Renew Three-Year Term as Americas Director of Leading Data Sciences Organization PhUSE
CANTON, Mich. (November 2, 2018) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that one of its leader’s in programming and data sciences, Chris Hurley, has been asked and has accepted a second three-year term as Americas Director of PhUSE – an independent, global organization for more than 8,000 data managers, biostatisticians, clinical programmers, and eClinical IT professionals.
MMS Submission Support for Paratek Pharmaceuticals Garners FDA Approval and Successful MAA Filing of NUZYRA™ (Omadacycline)
MMS announced today their expert support to Paratek Pharmaceuticals, Inc. for the new drug application (NDA) approval and successful marketing authorisation application (MAA) filing of NUZYRA™ (omadacycline) for…
Detroit-Area Life Sciences Firm Pledges More Than $250,000 in Employee Hours to Local Volunteer Initiatives
CANTON, Mich. (October 5, 2018) – MMS Holdings Inc. (MMS) – award-winning, data-focused CRO – announced today its renewed dedication to the local communities surrounding Detroit and Ann Arbor by allocating a substantial amount of colleague time to volunteer initiatives over the next year. Re-launched as part of its #OneMMS campaign, the value of this investment locally is worth $251,640.
UNITED KINGDOM (August 23, 2018) – MMS Holdings Inc. (MMS) – an award-winning, global clinical research organization – announced today that it has won the award for Best Global Biotech CRO in the International Life Sciences Awards 2018 by Global Health & Pharma (GHP) magazine.
This Saturday, MMS is hosting their annual Scientific Symposium India at its Asian headquarters in Bangalore, India. RSVP now at: Asia@mmsholdings.com
MMS Supported Clinical Data Aspects in Gemphire Therapeutics Meeting its Primary Endpoint in Gemcabene Study
Canton, Mich. (July 10, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today its integrated support for Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH). MMS supported data aspects for Gemphire in achieving its primary endpoint…
Durham, N.C. (June 13, 2018) – MMS Holdings Inc. (MMS) – a leading global clinical research organization – announced today that Lisa James has joined as Director, Business Operations and Client Relations. James brings a depth of industry and business experience, having most recently held the position as Director of Corporate Operations at Health Decisions, Inc.